Home
SCIO Path to Approval
Early Clinical Research
Strategy and TPP
Translational Medicine and Epigenetics
Biologics, Cell and Gene Therapy
Real World Evidence
Repurposing
Orphan Drug Solutions
Biomarkers and Surrogate Endpoints
Regulatory Affairs FDA and EMA
Medical Affairs and Clinical Research
Due Diligence
Trial Management & Trial Rescue
People
Senior Advisors
Candida Fratazzi
Claudio Carini
Federico Goodsaid
Our Clients
Our Collaborators
Testimonials
Resources
BBCR Voice
Case Studies
Published Studies
Conferences & Presentations
Job Opportunities
Contact Info
Select Page
`
Tagged: SCIO
Innovative Strategies Address Risks Related to Multiple Sclerosis Treatments
May 21st, 2019 | SCIO
Drug development success hinges on simplifying Clinical Research
May 16th, 2019 | SCIO
Strategic Consulting: The convergence revolution to innovate clinical trial process
May 10th, 2019 | SCIO
Strategic Consulting – SCIO Process -A New Way for Drug Development
April 30th, 2019 | SCIO
Strategic consulting reduces cost and risk of clinical trials
April 2nd, 2019 | SCIO
SCIO Helps Early Stage Biotech Company Evaluation
January 24th, 2019 | SCIO
Welcome to BBCR’s New Website!
December 7th, 2018 | SCIO
Newer posts »
Search for:
Categories
Biomarkers & Surrogate Endpoints
Company News
Drug Development
Due Diligence
Early Clinical Development
Industry News
Medical Affairs and Clinical Research
Miscellaneous
Orphan Diseases
Pre-IND
Precision Medicine
Rare Disease
Real World Evidence
Regulatory
Regulatory Affairs
Strategy and TPP
Translation Medicine and Epigenetics
Trial Management
Trial Rescue
Recent Posts
At BBCR, our team of seasoned experts is dedicated to helping clients navigate the intricate landscape of rare genetic conditions and unsolved diseases. We work hand in hand with product developers to create the most effective strategies for bringing innovative treatments to market.
Our experienced CRO Management and Drug development team identify study remediation strategies and provide a resource for any Study Rescue. We invite you to reach out to learn more – visit bbcrconsulting.com.
A pioneering figure in the area of rare diseases and orphan drug early-stage clinical research and regulatory strategies, Dr. Candida Fratazzi has an impressive 25-year track record in this specialized field.
BBCR is committed to cultivating and enhancing a product’s unique strengths at every stage, from initial conception to successful market launch. With deep expertise in cell therapy, biologics, and gene therapy—particularly in the realm of rare diseases—we provide strategic guidance and innovative solutions that form the foundation of our consultancy practice.
BBCR embraces innovative strategic consulting for highly effective clinical development planning and regulatory strategy. Reach out today to learn more about how we can help advance your project.